# Neuroinflammation (The gut-brain axis) and its role in Alzheimer's Disease by Dr Basmah Alrowaily







Hippocrates, the ancient Greek physician, believed that all diseases originate in the gut, which has been an influential concept in the modern understanding of the gut-brain axis. There has been growing evidence indicating that the gut microbiota has a significant impact on the development and progression of neurodevelopmental and neurodegenerative diseases through the communication pathway known as the gut-brain axis. Recent discoveries suggest that gut health could serve as a useful early indicator for Alzheimer's disease (AD), which could lead to improved treatment and management of symptoms for both AD and gut-related conditions.

Individuals with a genetic susceptibility to neurodegenerative diseases, like Alzheimer's disease, may be at increased risk of developing the condition due to exposure to common peptides shared between humans and gut microbes. The gut microbiota can release byproducts, including amyloids and lipopolysaccharides, into the gut environment, which may be absorbed and lead to alterations in inflammatory cytokine signaling pathways that contribute to the development and accumulation of Alzheimer's disease. Changes in the gut microbiota can also disrupt the proper functioning of microglia in the central nervous system, potentially contributing indirectly to the pathogenesis of neurodegenerative diseases.

Research has indicated that alterations in the composition of gut microbiota, specifically with regard to certain species including Bacteroides, Lactobacillus, Clostridium, and Bifidobacterium, can impact brain function in humans. These findings lend support to the hypothesis that the gut microbiome may play a role in the development of diseases such as Alzheimer's disease.Several research studies have demonstrated that the use of probiotics and dietary modifications can lead to enhanced cognitive function and reduced accumulation of Alzheimer's disease-associated markers. Some studies have shown a link between amyloidosis, cognitive decline, and the release of pro-inflammatory cytokines by the gut microbiome.

(Dr Chinta Sidharthan)

(Dr Kanmani Suganya)

The excessive production and accumulation of amyloid peptides, as well as the migration of microbes and their byproducts, can penetrate the brain and potentially trigger neuroinflammation and degenerative changes in Alzheimer's disease. Leptin and ghrelin, among other gut peptides, are believed to impact cognitive processes such as memory and learning. Alzheimer's disease is a common neurodegenerative condition marked by the cognitive decline of these facets. A recent study examining the impact of changes in gut microbiota and associated immune/inflammatory effects in patients with neurological disorders discovered that in human subjects, there was an increase in cerebral accumulation and neuroinflammation.

Bacterial LPS was detected in the brain, and higher levels of IL-1β, NLRP3, and CXCL2 were found to be positively linked to the abundance of Escherichia/Shigella. It has been observed that the gut microbiota composition is altered in individuals with Alzheimer's Disease (AD), which may contribute to the pathogenesis of the disease. Elderly patients with AD have a lower abundance of bacteria that produce butyrate, and a higher proportion of taxa associated with neurological disorders and inflammation. In vitro studies show that stool samples from AD patients induce lower production of the anti-inflammatory protein p-glycoprotein compared to samples from healthy elderly individuals, suggesting that the association between gut microbiota and the brain involves modulation of gut homeostasis, which may increase inflammation and decrease anti-inflammatory responses and microbial metabolism.

The bidirectional communication between the gut microbiota and the central nervous system has been observed to positively influence the development and functioning of both systems, leading to improved gut homeostasis. Disruptions in brain function however, can impact the physiology of the gastrointestinal tract, including digestion and the composition of gut microbiota, and the reverse is also true. More investigation is necessary to establish a connection between the gut microbiome and cognitive disorders, as the gut microbiota composition in the elderly specifically, is strongly associated with their dietary habits and overall health condition. The objective of future research is to gain a comprehensive understanding of the mechanisms by which the microbiome influences the brain and to determine whether therapies targeted towards the gut microbiome could potentially treat cognitive disorders. Investigating the effects of therapeutic approaches such as probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation on the gut microbiota composition in patients with neurological disorders would be highly valuable in enhancing and re-evaluating our understanding of the gut-brain axis, its importance and the potential beneficial or harmful impact of the gut microbiota on brain function.